Jiangsu Hengrui Pharmaceuticals Co.,Ltd. (SSE: 600276) has disclosed its latest share repurchase progress, revealing that as of July 31, 2026, the company had cumulatively bought back 13.75 million shares through the Shanghai Stock Exchange's centralized bidding system. This represents 0.21% of the company's total share capital.

In July 2026 alone, the company purchased 280,000 shares via the same mechanism, accounting for 0.004% of total shares. The buyback price ranged from a high of RMB 54.05 per share to a low of RMB 53.75 per share, with a total expenditure of approximately RMB 15.09 million (excluding transaction fees).

For the entire buyback program as of July 31, the purchase price has fluctuated between a high of RMB 70.00 per share and a low of RMB 45.30 per share, with total spending reaching approximately RMB 853.08 million (excluding transaction fees).